The fast-tracking landscape of contemporary gene therapy demands continuous advances in AAV (Adeno-associated virus) formulation development and the enhancement of cGMP (Current Good Manufacturing Practice) capacity. Together, these transformations are essential in producing safe and effective gene therapies for patients.
AAV Formulation Development: A Primary Focus
In the field...
Dutch 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek